New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) vs Century Therapeutics, Inc. (IPSC)

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Century Therapeutics, Inc. are both Biotechnology companies. Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Century Therapeutics, Inc. are of similar size ($239.7M and $237.8M). Across the 1 metrics below, Century Therapeutics, Inc. leads on 1 and Clinuvel Pharmaceuticals Ltd. - Sponsored ADR on 0.

Valuation

Metric CUVL IPSC Biotechnology median
P/E — n/m 8.49
P/S — 2.10 8.56
P/B — 1.15 2.04
Price to free cash flow — n/m 23.84
EV/EBITDA — n/m 0.69
EV/Sales — 1.08 8.00
Earnings yield — (55.01%) (35.81%)
Free cash flow yield — (35.20%) (25.41%)

Profitability

Metric CUVL IPSC Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (28.42%) 0.00%
Net margin — (19.10%) 0.00%
Free cash flow margin — (99.74%) 0.00%
Return on equity — (51.16%) (51.58%)
Return on assets — (38.96%) (45.91%)
Return on invested capital — (71.47%) 0.00%

Growth

Metric CUVL IPSC Biotechnology median
Revenue growth (TTM) — 8,286.72% 7.20%
EPS growth (last fiscal year) (2.13%) 91.30% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CUVL IPSC Biotechnology median
Debt to equity — 0.00 0.00
Current ratio — 8.74 4.79
Net debt to EBITDA — 17.95 1.01

Dividend

Metric CUVL IPSC Biotechnology median
Dividend yield 0.62% — 0.41%
Payout ratio — — —

Size

Metric CUVL IPSC Biotechnology median
Market cap 237.81m 239.71m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack